Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC

被引：0
|
作者：
Aminu, Muhammad
Vokes, Natalie I.
Saad, Maliazurina B.
Li, Hui
Hong, Lingzhi
Mohamed, S. Mohamed
Boom, John
Chen, Pingjun
Altan, Mehmet
Gandhi, Saumil
Swisher, Stephen
Antonoff, Mara B.
Pozadzides, Jenny V.
Blumenschein, George, Jr.
Gibbons, Don L.
Cascone, Tina
Elamin, Yasir Y.
Le, Xiuning
Negrao, Marcelo V.
Skoulidis, Ferdinandos
Tsao, Anne S.
Tu, Janet
Lee, J. Jack
Zhang, Jianjun
Heymach, John V.
Wu, Jia
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4393
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4393
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease
    Lynch, Connor
    Arshad, Muzamil
    Katipally, Rohan R.
    Pitroda, Sean P.
    Weichselbaum, Ralph R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (29)
  • [22] High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
    McGrail, D. J.
    Pilie, P. G.
    Rashid, N. U.
    Voorwerk, L.
    Slagter, M.
    Kok, M.
    Jonasch, E.
    Khasraw, M.
    Heimberger, A. B.
    Lim, B.
    Ueno, N. T.
    Litton, J. K.
    Ferrarotto, R.
    Chang, J. T.
    Moulder, S. L.
    Lin, S-Y
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 661 - 672
  • [23] DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma
    Ressler, Julia Maria
    Tomasich, Erwin
    Hatziioannou, Teresa
    Ringl, Helmut
    Heller, Gerwin
    Silmbrod, Rita
    Gottmann, Lynn
    Starzer, Angelika Martina
    Zila, Nina
    Tschandl, Philipp
    Hoeller, Christoph
    Preusser, Matthias
    Berghoff, Anna Sophie
    TARGETED ONCOLOGY, 2024, 19 (02) : 263 - 275
  • [24] DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma
    Julia Maria Ressler
    Erwin Tomasich
    Teresa Hatziioannou
    Helmut Ringl
    Gerwin Heller
    Rita Silmbrod
    Lynn Gottmann
    Angelika Martina Starzer
    Nina Zila
    Philipp Tschandl
    Christoph Hoeller
    Matthias Preusser
    Anna Sophie Berghoff
    Targeted Oncology, 2024, 19 : 263 - 275
  • [25] Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC
    Ochoa-de-Olza, Maria
    Bourhis, Jean
    Coukos, George
    Herrera, Fernanda G.
    LANCET ONCOLOGY, 2022, 23 (04): : E157 - E157
  • [26] Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma
    Gambichler, T.
    Seifert, C.
    Lehmann, M.
    Lukas, C.
    Scheel, C.
    Susok, L.
    IMMUNOTHERAPY, 2020, 12 (07) : 439 - 444
  • [27] Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression
    Xu, Yingqi
    Xu, Jianlin
    Qiao, Rong
    Zhong, Hua
    Xia, Jinjing
    Zhong, Runbo
    TRANSLATIONAL ONCOLOGY, 2023, 33
  • [28] Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
    Guo, Ya
    Zhang, Yin Bin
    Li, Yi
    Su, Wang Hui
    He, Shan
    Pan, Shu Pei
    Xu, Kun
    Kou, Wei Hua
    INTERNATIONAL JOURNAL OF GENOMICS, 2022, 2022
  • [29] Associations of intragenic rearrangement burden with immune cell infiltration and response to immune checkpoint blockade in cancer
    Zhang, Han
    Lee, Sanghoon
    Muthakana, Renee R.
    Lu, Binfeng
    Boone, David N.
    Lee, Daniel
    Wang, Xiaosong
    CANCER RESEARCH, 2024, 84 (06)
  • [30] Intragenic Rearrangement Burden Associates with Immune Cell Infiltration and Response to Immune Checkpoint Blockade in Cancer
    Zhang, Han
    Lee, Sanghoon
    Muthakana, Renee R.
    Lu, Binfeng
    Boone, David N.
    Lee, Daniel
    Wang, Xiao-Song
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (03) : 287 - 295
12345